Pulmonary arterial hypertension – Page 2

Merck’s WINREVAIR Receives EU Approval for Pulmonary Arterial Hypertension Treatment

8 months ago talkbio0Tagged 4-aminohippuric acid, Approved, EU, Merck, Pulmonary arterial hypertension, Winrevair

WINREVAIR, Merck, EU Approval, Pulmonary Arterial Hypertension, PAH Treatment

Liquidia’s Yutrepia Receives Tentative FDA Approval Due to Tyvaso Exclusivity

8 months ago talkbio0Tagged 4-aminohippuric acid, exclusivity, Liquidia, PH-ILD, Pulmonary arterial hypertension, Tentative Approval, Tyvaso, United States Food and Drug Administration, YUTREPIA

Liquidia, Yutrepia, FDA, tentative approval, Tyvaso, exclusivity, pulmonary arterial hypertension, PAH, PH-ILD

FDA Grants Tentative Approval for YUTREPIA, a New Treatment for Pulmonary Arterial Hypertension and Pulmonary Hypertension Associated with Interstitial Lung Disease

8 months ago talkbio0Tagged Associated with, Lung Diseases, Interstitial, PH-ILD, Pulmonary arterial hypertension, Pulmonary Hypertension, regulatory exclusivity, Tentative Approval, Tyvaso, United States Food and Drug Administration, United Therapeutics, YUTREPIA

YUTREPIA, treprostinil, pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), FDA tentative approval, regulatory exclusivity, United Therapeutics, Tyvaso

Aerovate Therapeutics’ Shares Plummet 93.3% After Disappointing IMPAHCT Study Results for AV-101 in Pulmonary Arterial Hypertension

10 months ago talkbio0Tagged 4-aminohippuric acid, Aerovate, AV-101, Biotech Stocks, Clinical Trials, Drug Formulation Process, imatinib, IMPAHCT, Inspiration function, Pulmonary arterial hypertension

Aerovate Therapeutics, AV-101, IMPAHCT Study, Pulmonary Arterial Hypertension, PAH, Imatinib, Inhaled Formulation, Biotech Stocks, Clinical Trials